Skip to Content
Notice

Manufacturer of Controlled Substances; Notice of Application

 

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 22, 2011, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug Schedule
Codeine-N-oxide (9053) I
Dihydromorphine (9145) I
Morphine-N-oxide (9307) I
Amphetamine (1100) II
Methylphenidate (1724) II
Codeine (9050) II
Dihydrocodeine (9120) II
Oxycodone (9143) II
Hydromorphone (9150) II
Hydrocodone (9193) II
Morphine (9300) II
Oripavine (9330) II
Thebaine (9333) II
Oxymorphone (9652) II
Noroxymorphone (9668) II
Alfentanil (9737) II
Sufentanil (9740) II
Carfentanil (9743) II
Tapentadol (9780) II
Fentanyl (9801) II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 30, 2012.

Dated: November 21, 2011.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 2011-30685 Filed 11-28-11; 8:45 am]

BILLING CODE 4410-09-P

Site Feedback